Transaction DateRecipientSharesTypePriceValue
31st December 2020Paul Edward Walker222Open or private sale$141.28$31,364.65
31st December 2020David M Mott2,158Grant/award etc.$10.86$23,435.88
31st December 2020Paul Edward Walker1,499Open or private sale$139.88$209,684.92
31st December 2020Paul Edward Walker33,302Open or private sale$140.48$4,678,328.23
30th December 2020Paul Edward Walker7,144Open or private sale$143.07$1,022,056.36
30th December 2020Paul Edward Walker25,109Open or private sale$141.78$3,559,883.71
30th December 2020Paul Edward Walker34,931Open or private sale$141.31$4,936,190.43
30th December 2020Peter J Barris5,229Grant/award etc.$0.00
30th December 2020Paul Edward Walker1,208Open or private sale$143.81$173,722.24
14th December 2020David M Mott486Other acquisition or disposition$0.00
Regulus Therapeutics
Regulus Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Regulus Therapeutics, Inc. is a biopharmaceutical company. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases.

Ticker: RGLS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1505512
Employees: 21
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $23 M (0%)
Other Assets, Current: $573 Th (-53%)
Assets, Current: $29 M (-29%)
Property, Plant and Equipment, Net: $684 Th (-25%)
Other Assets, Noncurrent: $387 Th (-20%)
Assets: $30 M (-29%)
Accounts Payable, Current: $1 M (-22%)
Accrued Liabilities, Current: $1 M (17%)
Liabilities, Current: $21 M (-2%)
Other Liabilities, Noncurrent: $217 Th (-53%)
Liabilities: $21 M (-3%)
Common Stock, Value, Issued: $36 Th (71%)
Common Stock, Shares, Issued: $36 M (70%)
Additional Paid in Capital, Common Stock: $433 M (0%)
Retained Earnings (Accumulated Deficit): $424 M (3%)
Stockholders' Equity (Parent): $9 M (0%)
Liabilities and Equity: $30 M (-29%)
Research and Development: $4 M (-42%)
General and Administrative Expenses: $2 M (-51%)
Operating Income/Loss: $6 M (-46%)
Provision for income taxes: $0 (-100%)